Treatment of ankylosing spondylitis with biologic agents
No Thumbnail Available
Date
2010
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Ankylosing spondylitis (AS) is a chronic inflammatory disorder of the spine that can lead to significant disability if left untreated. Although conventional treatments can be successful in alleviating symptoms, they have not been shown to stop progression of the disease. The proinflammatory cytokine tumor necrosis factor (TNF) is central to the pathogenesis of AS. Several TNF-αblocker drugs such as infliximab, adalimumab, etanercept and golimumab have been developed and shown to control symptoms effectively, possibly preventing both clinical and radiographic progression of the disease in patients with AS. Acute inflammatory lesions in the spine and sacroiliac joints can be effectively suppressed by the TNF-αblockers in AS, suggesting that bone destruction and bone proliferation might be prevented. © 2010 Bentham Science Publishers Ltd.
Description
Keywords
adalimumab , etanercept , golimumab , infliximab , methotrexate , nonsteroid antiinflammatory agent , salazosulfapyridine , ankylosing spondylitis , clinical trial , disease course , drug dose increase , drug megadose , drug withdrawal , human , low drug dose , review , rheumatoid arthritis , treatment response , treatment withdrawal